Clinically, GLP-1RAs are used to treat people with T2D and/or obesity (Figure 1), based on mechanisms described above linked to control of insulin and glucagon secretion, as well as reduction of food intake. The gene discussed is GCG; the disease is type 2 diabetes mellitus.